Advanced Search
DENG Lian-bai, LI Ai-xiu, JIN Yu-rui. Advances in the study on inhibitors of RNase H,a novel anti-HIV drug target[J]. Journal of China Pharmaceutical University, 2011, 42(6): 578-584.
Citation: DENG Lian-bai, LI Ai-xiu, JIN Yu-rui. Advances in the study on inhibitors of RNase H,a novel anti-HIV drug target[J]. Journal of China Pharmaceutical University, 2011, 42(6): 578-584.

Advances in the study on inhibitors of RNase H,a novel anti-HIV drug target

More Information
  • As the infection of the acquired immunodeficiency syndrome (AIDS) and the mutation of the HIV virus keep increasing,there’s an urgent demand for developing new anti-HIV drugs.Up till now,the research on anti-HIV agents has been carried out in two ways:based on known targets or new targets.Ribonuclease H (RNase H),which has with its own unique catalytic sites of enzyme function and is regarded as a novel drug target for anti-HIV therapy,is a domain of the reverse transcriptase.This review summarizes RNase H inhibitors discovered in recent years and explains their mechanisms of action which aims at providing some useful information for further structural modifications and design of RNase H inhibitors.
  • Related Articles

    [1]ZHU Zhixi, ZHANG Jielin, CHEN Yijun. Recent advances in research on chelators as metallo-β-lactamase inhibitors[J]. Journal of China Pharmaceutical University, 2022, 53(4): 410-422. DOI: 10.11665/j.issn.1000-5048.20220404
    [2]YANG Qian, WANG Xiaojian. Research progress of sphingosine kinase 1 inhibitors[J]. Journal of China Pharmaceutical University, 2021, 52(6): 759-768. DOI: 10.11665/j.issn.1000-5048.20210615
    [3]YUAN Zhong, CHEN Zhuo, LI Qianbin, HU Gaoyun. Advances in research of protein tyrosine phosphatase 1B and its inhibitors[J]. Journal of China Pharmaceutical University, 2018, 49(1): 1-9. DOI: 10.11665/j.issn.1000-5048.20180101
    [4]GUO Yahui, LU Peng, WANG Yubin, ZHANG Huibin. Progress in the researches for antitumor NEDD8 activating enzyme inhibitors[J]. Journal of China Pharmaceutical University, 2017, 48(6): 646-653. DOI: 10.11665/j.issn.1000-5048.20170603
    [5]CHENG Yulan, MEN Jinxia, ZHOU Jinpei, ZHANG Huibin. Advances in indoleamine 2, 3-dioxygenase 1 inhibitors[J]. Journal of China Pharmaceutical University, 2017, 48(3): 361-370. DOI: 10.11665/j.issn.1000-5048.20170318
    [6]WU Shiwei, ZHANG Hui, LI Qianbin, HU Gaoyun. Advances in thioredoxin reductase and its inhibitors[J]. Journal of China Pharmaceutical University, 2016, 47(5): 511-520. DOI: 10.11665/j.issn.1000-5048.20160502
    [7]XIN Minhang, ZHANG Sanqi. Advances in PI3Kδ selective inhibitors[J]. Journal of China Pharmaceutical University, 2016, 47(5): 503-510. DOI: 10.11665/j.issn.1000-5048.20160501
    [8]LIU Kejun, ZHANG Zhimin, RAN Ting, CHEN Hongli, LU Tao, CHEN Yadong. Advances in BET bromodomain protein inhibitors[J]. Journal of China Pharmaceutical University, 2015, 46(3): 264-271. DOI: 10.11665/j.issn.1000-5048.20150302
    [9]LI Chunhong, DU Hongjin, WEN Xiao′an, SUN Hongbin. Advances in inhibitors of MDM2 and MDM4[J]. Journal of China Pharmaceutical University, 2015, 46(1): 1-15. DOI: 10.11665/j.issn.1000-5048.20150101
    [10]SUN Zhan-yi, CAI Hui, HUANG Zhi-hua, SHI Lei, CHEN Yong-xiang, LI Yan-mei. Advances of glycopeptide-associated tumor vaccines[J]. Journal of China Pharmaceutical University, 2012, 43(2): 97-106.

Catalog

    Article views (1354) PDF downloads (1857) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return